Yulong Eco-Materials

Yulong Eco-Materials Ltd. engages in the manufacture and sale of fly-ash bricks and concrete. It operates through the following business divisions: Yulong Bricks, Yulong Concrete and Yulong Transport, and Yulong Renewable. The Yulong Bricks division produces and sells fly-ash bricks. The Yulong Concrete and Yulong Transport division relates to the production and sale of ready-mixed concrete. The Yulong Renewable division includes hauling and processing of construction waste, and production and sales of recycled aggregates and recycled bricks. The company was founded by Zhu Yu Long on March 10, 2011 and is headquartered in Cheyenne, WY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TAMPA, FL / ACCESSWIRE / October 2, 2023 / EV Biologics Corp, (OTC Pink:YECO), today announced that it has closed a $500,000 interest-free loan from a related party. This funding will provide for further development of exosome - and other nanoparticle-enriched biological products, as well as optimization of their scalable, cGMP-compatible, biomanufacturing process.

EV Biologics Updates on Funding and Sales

TAMPA, FL / ACCESSWIRE / August 16, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product. Rigorous product analysis has already begun, and the Company has engaged leading independent testing laboratories to perform sophisticated analyses of molecular composition, therapeutic activity, and any potential forms of contamination, to thoroughly validate the product and prepare comprehensive product data specifications that are second to none.

EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic

TAMPA, FL / ACCESSWIRE / August 7, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has appointed William Bossung as Corporate Finance Director. Mr. Bossung brings a wealth of experience as a long-time investment banker, with 5 decades of experience serving as a director and dealing with NYSE and NASDAQ companies.

EV Biologics Appoints Senior Investment Banker as Corporate Finance Director

TAMPA, FL / ACCESSWIRE / August 2, 2023 / EV Biologics Corp (OTC PINK:YECO) today announced that it has hired Monte Fisher as Chief Financial Officer. Mr. Fisher brings a wealth of experience as a long-time senior employee of Shell Oil, based in Houston, Texas where he held key leadership roles within Shell Finance.

EV Biologics Hires Senior Chief Financial Officer

TAMPA, FL / ACCESSWIRE / May 15, 2023 / EV Biologics Corp (OTC PINK:YECO), today announced that it has signed an exclusive multi-year agreement with INNOVARE for distribution in South America. This agreement will facilitate the launch, in South America and the Caribbean, of EV Biologics regenerative health products, which are currently in production by its wholly owned subsidiary, EXCYTE.

EV Biologics Signs Exclusive Distribution Agreement for South America

TAMPA, FL / ACCESSWIRE / February 21, 2023 / EV Biologics Corp (OTC PINK:YECO), today announced that it has successfully generated several mesenchymal stem/stromal cell (MSC) lines for secretome production and further cell line development. The cell banks were isolated from rigorously screened human donor tissue using xeno-free, serum-free culture media for isolation and expansion, after obtaining informed consent (from donors) for research and development.

EV Biologics Generates Mesenchymal Stem Cell Lines

TAMPA, FL / ACCESSWIRE / January 3, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has now closed $1,000,000 of its $2.5 million initial capitalization goal. One hundred thousand shares (100,000) have been issued at $10 per share, out of a total issuance of ten million shares to EV Biologics.

EV Biologics Updates on Excyte Subsidiary Funding

TAMPA, FL / ACCESSWIRE / November 14, 2022 / EV Biologics Corp, (OTC PINK:YECO), today announced that it is initiating a PCAOB audit for 2021 and 2022 and intends to file an application to list on the OTCQX market during Q1, 2023. This PCAOB audit is a necessary step to finalize the previously filed corporate name change with FINRA, which will also update the trading symbol.

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

TAMPA, FL / ACCESSWIRE / August 15, 2022 / EV Biologics Corp, OTC Pink: YECO, today announced that it has launched Excyte, Inc., a wholly owned subsidiary, with $100 Million valuation. Excyte has already raised $500,000 of its $2.5 million initial capitalization goal.

EV Biologics Launches Excyte with $100 million Valuation

HOUSTON, TX / ACCESSWIRE / May 17, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has signed a Manufacturing Services Agreement (MSA) with Lonza for development of stem/progenitor cell-derived nanotherapeutics and scalable biomanufacturing process. The MSA enables EV Biologics to accelerate its nanotherapeutic biomanufacturing process and producer-cell line development through Lonza's global infrastructure and deep expertise in cell and gene therapy.

EV Biologics Signs MSA with LONZA Cell & Gene Therapy

TAMPA, FL / ACCESSWIRE / April 12, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has succeeded in isolating primary progenitor cells from tissue using a xeno-free process. The Company has been developing an improved process for isolation of progenitor cells from tissue to generate cell banks for therapeutic nanoparticle production and further cell line development.

EV Biologics Isolates Primary Cells for Nanoparticle Production & Accelerated Cell Line Development

NASHVILLE, TN / ACCESSWIRE / March 9, 2022 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with the latest information about its submitted FINRA applications for name change and NFT dividend distribution. The Company announced on August 6, 2020, that it had submitted its name change filing with FINRA.

EV Biologics Updates on FINRA Filings

NASHVILLE, TN / ACCESSWIRE / January 18, 2022 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with further details about its submitted FINRA applications for name change and NFT dividend distribution. The Company is still awaiting approval from FINRA for the NFT dividend distribution.

EV Biologics Updates on FINRA

NASHVILLE, TN / ACCESSWIRE / November 12, 2021 / EV Biologics Corp, (OTC PINK:YECO), today updated shareholders with further details about its NFT dividend. The Company is still awaiting approval from FINRA for the distribution of the dividend.

EV Biologics Updates on NFT Dividend

NASHVILLE, TN / ACCESSWIRE / November 11, 2021 / EV Biologics Corp, ("the Company"), OTC PINK:YECO, today confirmed that it has signed an agreement to list its common stock on the INX Securities ATS, a regulated alternative trading system operated by INX Securities, LLC. INX Securities, LLC is the FINRA-member broker-dealer subsidiary of INX Limited.

EV Biologics Signs Listing Agreement With INX

NASHVILLE, TN / ACCESSWIRE / October 28, 2021 / EV Biologics Corp, OTC Pink:YECO, today updated shareholders about a recent publication authored by its Chief Medical Officer, Dr. Jason Sanders. This review discusses some of the cellular and molecular pathology of COVID-19 and the relevant therapeutic mechanisms of small extracellular vesicles (EVs), such as exosomes, in Acute Lung Injury (ALI).

EV Biologics Chief Medical Officer Publication on COVID-19 & Exosomes

NASHVILLE, TN / ACCESSWIRE / September 28, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with further details about its NFT and minting progress. Our NFT team has been minting the NFT, designated rEVerie, on the Ghostmarket.io platform, with an estimated completion date this week.

EV Biologics Updates on NFT Minting

NASHVILLE, TN / ACCESSWIRE / August 30, 2021 / EV Biologics Corp, (OTC Pink:YECO), today updated shareholders with further details about its NFT Warrant Dividend distribution. The Company is currently finalizing its filing with FINRA, and then will have its transfer agent issue the dividend Warrant through DTC.

EV Biologics Updates on NFT Warrant Dividend Distribution

NASHVILLE, TN / ACCESSWIRE / August 12, 2021 / EV Biologics Corp, OTC Pink:YECO, today briefed shareholders on its current value compared to other public biotechnology companies in its peer group. Please view the chart at: https://www.evbiologics.com/marketcap/.

EV Biologics Briefs Shareholders on Market Cap Peer Comparison

NASHVILLE, TN / ACCESSWIRE / August 9, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with further details about its NFT Warrant Dividend. Attached is a preliminary image from the 3D animation still under development that will be issued as an NFT dividend Daniel Mckinney CEO said: "this NFT will capture the stunning visual quality inherent in many biological systems, as in this artistic rendering of a fluorescent micrograph of a group of stem cells.

EV Biologics NFT Dividend Information

NASHVILLE, TN / ACCESSWIRE / July 30, 2021 / EV Biologics Corp., OTC PINK:YECO, today confirmed for share holders its NFT Warrant Dividend shareholders-of-record date. YECO's shareholders-of-record on July 30, 2021 will receive the Warrant.

EV Biologics NFT Dividend Warrant Date

NASHVILLE, TN / ACCESSWIRE / July 28, 2021 / EV Biologics Corp, OTC PINK:YECO today announced that it has signed an agreement with Lonza Cell Bio Services to implement a custom cell isolation in preparation for a novel, clonal, master cell bank. These cells will also be used in optimization of the process for production of therapeutically active, native, extracellular vesicles and particles (EVP).

EV Biologics Starts Custom Cell Isolation with Lonza Cell Bio Services

NASHVILLE, TN / ACCESSWIRE / July 26, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders about its NFT dividend Warrant. The Company will distribute one (1) Warrant for every 100 shares of YECO common stock held.

EV Biologics Unveils NFT Dividend Warrant

NASHVILLE, TN / ACCESSWIRE / July 22, 2021 / EV Biologics Corp., (OTC PINK:YECO) today announced that it has signed a Letter of Intent (LOI) with Lonza Cell & Gene Therapy for Process Development and Gap Analysis for biomanufacturing of a novel therapeutic composition, comprising extracellular vesicles (EVs) and particles, as well as other secreted factors derived from selected stem/progenitor cells, such as mesenchymal stromal cells (MSCs). Lonza is one of the leading global manufacturers serving the biotechnology and pharmaceutical industries.

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

NASHVILLE, TN / ACCESSWIRE / July 19, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders about its NFT dividend. On July 14, 2021 the Company announced a dividend of 1 NFT for every 100 shares of YECO common stock.

News for Yulong Eco-Materials Stock (YECO)